Expression of p53 and bcl-2 in clinically localized prostate cancer before and after neo-adjuvant hormonal therapy

Oncology Research

Volumn 12, Issue 1, 2000, Pages 43-49

  Cesinaro, Anna M ^a   Migaldi, Mario ^a   Ferrari, Giovanni ^b   Castagnetti, Giovanni ^b   Dotti, Alberto ^b   De Gaetani, Carmela ^a   Ferrari, Paolo ^b   Trentini, Gian P ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b AUSL Modena   (Italy)

Author keywords

bcl 2; Hormonal therapy; Hormone resistance; p53; Prognosis; Prostate cancer

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; GONADORELIN; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

AGED; ARTICLE; CANCER STAGING; DRUG RESISTANCE; ENZYME IMMUNOASSAY; HUMAN; LYMPH NODE; MALE; METABOLISM; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY, NEEDLE; DRUG RESISTANCE, NEOPLASM; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034567449     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000001108747435     Document Type: Article

References (42)

1. Nigro, J. M.; Baker, S. J.; Preisinger, A. C.; Jessup, J. M.; Hostetter, R.; Cleary, K.; Bigner, S. H.; Davidson, N. Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705-708; 1989.
2. Cattoretti, G.; Rilke, F.; Andreola, S.; D'Amato, L.; Delia, D. p53 expression in breast cancer. Int. J. Cancer 41:178-183; 1988.
3. Van der Berg, F. M.; Tigges, A. J.; Schipper, M. E. I.; Den Hartog-Jager, F. C. A.; Kroes, W. G. M.; Walboomers, J. M. M. Expression of the nuclear oncogene p53 in colon tumours. J. Pathol. 157:193-199; 1989.
4. Wright, C.; Mellon, K.; Johnston, P.; Lane, D. P.; Harris, A. L.; Horne, C. H. W. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the urinary bladder. Br. J. Cancer 63:967-970; 1991.
5. Navone, N. M.; Troncoso, P.; Pisters, L. L.; Goodrow, T. L.; Palmer, J. L.; Nichols, W. W.; von Eschenbach, A. C.; Conti, C. J. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst. 85:1657-1669; 1993.
6. Kallakury, B. V. S.; Figge, J.; Ross, J. S.; Fisher, H. A. G.; Figge, H. L.; Jennings, T. A. Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adcnocarcinoma. Hum. Pathol. 25:92-97; 1994.
7. Aprikian, A. G.; Sarkis, A. S.; Fair, W. R.; Zhang, Z-F.; Fuks, Z.; Cordon-Cardo, C. Immunohistochcmical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J. Urol. 151:1276-1280; 1994.
8. Visakorpi, T.; Kallioniemi, O. P.; Heikkincn, A.; Koivula, T.; Isola, J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst. 84:883-887; 1992.
9. Lu, Q-L.; Abel, P.; Foster, C. S.; Lalani, E-N. bcl-2: Role in epithelial differentiation and oncogenesis. Hum. Pathol. 27:102-110; 1996.
10. Bubendorf, L.; Sauter, G.; Moch, H.; Jordan, P.; Bloechlinger, A.; Gasser, T. C.; Mihatsch, M. J. Prognostic significance of bcl-2 in clinically localized prostate cancer. Am. J. Pathol. 148:1557-1565; 1996.
11. Moul, J. W.; Bettencourt, M-C.; Sesterhenn, I. A.; Mostofi, F. K.; McLeod, D. G.; Srivastava, S.; Bauer, J. J. Protein expression of p53, bcl-2 and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 120:159-167; 1996.
12. Colombel, M.; Symmans, F.; Gil, S.; O'Toole, K. M.; Chopin, D.; Benson, M.; Olsson, C. A.; Korsmeyer, S.; Buttyan, R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am. J. Pathol. 143:390-400; 1993.
13. Furuya, Y.; Lin, X. S.; Walsh, J. C.; Nelson, W. G.; Isaacs, J. T. Androgen ablation-induced programmed death of prostatic glandular cells docs not involve recruitment into a defective cell cycle or p53 induction. Endocrinology 136:1898-1906; 1995.
14. Dondi, D.; Moretti, R. M.; Montagnani Marelli, M.; Pratesi, G.; Polizzi, D.; Milani, M.; Motta, M.; Limonta, P. Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. Int. J. Cancer 76:506-511; 1998.
15. Noordzij, M. A.; Bogdanowicz, J. F. A. T.; van Krimpen, C.; van der Kwast, T. H.; van Steenbrugge, G. J. The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients. J. Urol. 158:1880-1885; 1997.
16. Stattin, P.; Westin, P.; Damber, J-E.; Bergh, A. Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer. Br. J. Cancer 77:670-675; 1998.
17. Heidenberg, H. B.; Sesterhenn, I. A.; Gaddipati, J. P.; Weghorst, C. M.; Buzard, G. S.; Moul, J. W.; Srivastava, S. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol. 154:414-421; 1995.
18. Berner, A.; Geitvik, G.; Karlsen, F.; Fossa, S. D.; Nesland, J. M.; Borresen, A. L. TP53 mutations in prostatic cancer. Analysis of pre- and post-treatment archival formalin-fixed tumour tissue. J. Pathol. 176:299-308; 1995.
19. Koivisto, P. A.; Rantala, I. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. J. Pathol. 187:237-241; 1999.
20. Gleason, D. F. The Veteran's Administration Cooperative Urologic Research Group: Histological grading and clinical staging of prostatic carcinoma. In: Tannenbaum, M., ed. Urologic pathology. The prostate. Philadelphia: Lea and Febiger; 1977:171-198.
21. Murphy, W. M.; Soloway, M. S.; Barrows, G. H. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 68:821-828; 1991.
22. Tetu, B.; Srigley, J. R.; Boivin, J.; Dupont, A.; Monfette, G.; Pinault, S.; Labrie, F. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Am. J. Surg,. Pathol. 15:111-120; 1991.
23. Smith, D. M.; Murphy, W. M. Histologic changes in prostate carcinoma treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentation. Cancer 73:1472-1477; 1994.
24. Stiens, R.; Helpap, B.; Weissbach, L. Quantitative investigation of cell loss in prostate carcinomas: Clinical-morphological aspects. Verh. Ges. Urol. 32:73-74; 1981.
25. Koivisto, P.; Kolmer, M.; Visakorpi, T.; Kallioniemi, O-P. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am. J. Pathol. 152:1-9; 1998.
26. Thomas, D. J.; Robinson, M.; King, P.; Hasan, T.; Charlton, R.; Martin, J.; Carr, T. W.; Neal, D. E. p53 expression and clinical outcome in prostate cancer. Br. J. Urol. 72:778-781; 1993.
27. Shurbaji, M. S.; Kalbfleisch, J. H.; Thurmond, T. S. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum. Pathol. 26:106-109; 1995.
28. Theodorescu, D.; Broder, S. R.; Boyd, J. C.; Mills, S. E.; Frierson, H. F., Jr. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J. Urol. 158:131-137; 1997.
29. Byrne, R. L.; Horne, C. H.; Robinson, M. C.; Autzen, P.; Apakama, I.; Bishop, R. I.; Neal, D. E.; Hamdy, F. C. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br. J. Urol. 79:190-195; 1997.
30. Bubendorf, L.; Tapia, C.; Gasser, T. C.; Casella, R.; Grunder, B.; Moch, H.; Mihatsch, M. J.; Sauter, G. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum. Pathol. 29:949-954; 1998.
31. Brewsler, S. F.; Oxley, J. D.; Trivella, M.; Abbott, C,. D.; Gillatt, D. A. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J. Urol. 161:1238-1243; 1999.
32. Bookstein, R.; MacGrogan, D.; Hilsenbeck, S. G.; Sharkey, F.; Allred, D. C. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 53:3369-3373; 1993.
33. Van Veldhuizen, P. J.; Sadasivan, R.; Garcia, F.; Austenfeld, M. S.; Stephens, R. L. Mutant p53 expression in prostate carcinoma. Prostate 22:23-30; 1993.
34. Wertz, I. E.; Deitch, A. D.; Gumerlock, P. H.; Gandur-Edwards, R.; Chi, S-G.; de Vere White, R. W. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Hum. Pathol. 27:573-580; 1996.
35. Baretton, G. B.; Klenk, U.; Diebold, J.; Schmeller, N.; Lohrs, U. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: Prognostic significance of p21/WAF1/CIP1 expression. Br. J. Cancer 80:546-555; 1999.
36. Moul, J. W. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur. Urol. 35:399-407; 1999.
37. Ruijter, E.; van-de-Kaa, C.; Aalders, T.; Ruiter, D.; Miller, G.; Debruyne, F.; Schalken, J. Heterogeneous expression of E-cadherin and p53 in prostate cancer: Clinical implications. BIOMED-II Markers for Prostate Cancer Study Group. Mod. Pathol. 11: 276-281; 1998.
38. Keshgegian, A. A.; Johnston, E.; Cnaan, A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am. J. Clin. Pathol. 110:443-449; 1998.
39. McDonnell, T. J.; Troncoso, P.; Brisbay, S. M.; Logothetis, C.; Chung, L. W. K.; Hsieh, J-T.; Tu, S-M.; Campbell, M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52:6940-6944; 1992.
40. Westin, P.; Stattin, P.; Damber, J-E.; Bergh, A. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am. J. Pathol. 146: 1368-1375; 1995.
41. Woolveridge, I.; Taylor, M. F.; Wu, F. C. W.; Morris, I. D. Apoptosis and related genes in the rat ventral prostate following androgen ablation in response to ethane dimethanesulfonate. Prostate 36:23-30; 1998.
42. Lowe, S. W.; Bodis, S.; McClatchey, A.; Remington, L.; Earl Ruley, H.; Fisher, D. E.; Housman, D. E.; Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810; 1994.